• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Response to clopidogrel is associated with early neurological deterioration after acute ischemic stroke.
Conclusions: CR and END are fairly common after acute IS. CR is associated with higher risk of END. Clopidogrel plus aspirin combination therapy provides greater inhibition of platelet aggregation, and may afford protection against END. PMID: 29731992 [PubMed]
Source: Oncotarget - May 9, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke.
Conclusions: Among IS patients treated with clopidogrel, carriers of a reduced-function CYP2C19 allele had a significantly higher rate of adverse vascular events than did noncarriers. It should avoid prescribing clopidogrel to these patients with known CYP2C19 polymorphisms. PMID: 29707143 [PubMed]
Source: Oncotarget - May 2, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013
CONCLUSIONSAmong CS and NCP with AMI in Ontario, similar improvements in mortality and receipt of treatments were observed between 1995 and 2013. However, compared with NCP, CS had a higher risk of mortality and heart failure. Cancer 2017. © 2017 American Cancer Society.
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Inna Y. Gong, Andrew T. Yan, Dennis T. Ko, Craig C. Earle, Winson Y. Cheung, Stuart Peacock, Marlous Hall, Chris P. Gale, Kelvin K. W. Chan Tags: Original Article Source Type: research

Clopidogrel-induced refractory thrombotic thrombocytopenic purpura successfully treated with rituximab
Publication date: Available online 2 December 2015 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Sara Khodor, Miguel Castro, Colin McNamara, Chakra P. Chaulagain Thrombotic thrombocytopenic purpura (TTP) is a multisystem disorder characterized by microvascular aggregation of platelets and fibrin strands causing thrombocytopenia, microangiopathic hemolytic anemia, and organ dysfunction. TTP can develop as a result of a deficiency in ADAMTS13 enzyme activity due to either a genetic defect or, more commonly, the development of anti-ADAMTS13 autoantibodies. TTP can also be associated with pregnancy, organ t...
Source: Hematology Oncology and Stem Cell Therapy - March 7, 2016 Category: Cancer & Oncology Source Type: research